FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:301-302 July 27, 2000 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: In 1989, a killed hepatitis A virus (HAV) vaccine produced from cell culture was described.¹ Today, several vaccines are available commercially in countries all over the world. The World Health Organization and other advisory committees now recommend the use of these vaccines for prophylactic purposes as well as for intervention during epidemics.² It is uncertain whether persons who are vaccinated after coming into contact with patients with hepatitis A can nevertheless become infected and possibly excrete infectious HAV without clinical symptoms, thus posing a risk to others. We describe the spread of symptomatic hepatitis A infection among . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Karayiannis, P., Main, J., Thomas, H. C. (2004). Hepatitis vaccines. Br Med Bull 70: 29-49 [Full Text]  
• Webster, G., Barnes, E., Dusheiko, G., Franklin, I. (2001). Protecting travellers from hepatitis A. BMJ 322: 1194-1195 [Full Text]